Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy

Minehiko Inomata,Shuhei Minatoyama,Naoki Takata,Kana Hayashi,Takahiro Hirai,Zenta Seto,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Kei Matsuyama,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe,MINEHIKO INOMATA,SHUHEI MINATOYAMA,NAOKI TAKATA,KANA HAYASHI,TAKAHIRO HIRAI,ZENTA SETO,KOTARO TOKUI,CHIHIRO TAKA,SEISUKE OKAZAWA,KENTA KAMBARA,SHINGO IMANISHI,TOSHIRO MIWA,KEI MATSUYAMA,RYUJI HAYASHI,SHOKO MATSUI,KAZUYUKI TOBE
DOI: https://doi.org/10.21873/anticanres.16920
2024-02-29
Anticancer Research
Abstract:BACKGROUND/AIM: Combined therapy with immune checkpoint inhibitors plus platinum doublet chemotherapy has a survival advantage over platinum doublet chemotherapy in patients with non-small cell lung cancer. However, a variety of factors make it difficult to administer treatment with platinum doublet chemotherapy in many patients in clinical practice and there are few reports on the efficacy and safety of first-line treatments with immune checkpoint inhibitors for patients who are ineligible for platinum doublet chemotherapy. This observational study aimed to evaluate the efficacy and safety of first-line immune checkpoint inhibitor therapy for this population.PATIENTS AND METHODS: We retrospectively assessed the survival and adverse events from the initiation of first-line immune checkpoint inhibitor therapy, including pembrolizumab or nivolumab plus ipilimumab in patients with non-small cell lung cancer who were ineligible for platinum doublet chemotherapy.RESULTS: Data from 48 patients were analyzed. Seventeen patients showed a performance status (PS) of ≥2 while 16 and 15 patients were considered ineligible for platinum doublet chemotherapy because of age and comorbidities, respectively. The median (95% confidential interval, CI) progression-free survival (PFS) and overall survival (OS) of the 48 patients were 7.1 (1.7-13.7) and 31.7 (8.8-not estimated) months, respectively. The two-year PFS and OS rates (95% CI) were 30.8% (18.2%-47.2%) and 50.7% (33.7%-67.7%), respectively. In patients with a PS of ≥2, the median (95% CI) PFS and OS were 1.6 (1.2-not estimated) and 5.5 (2.3-not estimated) months, respectively. The two-year PFS and OS rates (95% CI) were 34.3% (15.8%-59.2%) and 45.3% (22.2%-70.7%), respectively.CONCLUSION: Patients with non-small cell lung cancer and a PS of 0-1 who were ineligible for platinum doublet chemotherapy had favorable outcome after the initiation of ICI therapy, and even in patients with a PS of ≥2, they achieved high two-year PFS and OS rates.
oncology
What problem does this paper attempt to address?